In November 2001, Bayer and GlaxoSmithKline (GSK) signed a worldwide co-promotion and co-development agreement to launch a new treatment for men seeking to improve their erectile function. Since then, both companies have been working together on the development and future marketing of the product.

With these companies’ strong histories in healthcare and pharmaceuticals, the Bayer and GSK co-promotion represents a powerful alliance committed to improving men’s health through new treatment options.

More than half of all men over 40 have some symptoms of ED. An estimated 30 million men in the United States experience some degree of ED. Only one man in 10 seeks treatment for his decreased sexual function.

About Bayer
Best known for its flagship product, Bayer Aspirin, Bayer Corporation produces a broad range of healthcare, crop protection, polymer and chemical products that help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability and improve people’s lives.

Headquartered in Pittsburgh, Bayer Corporation had sales of $10.1 billion in 2001 and is one of Fortune magazine’s Most Admired Companies. The company employs 21,500 people. It is a member of the worldwide Bayer Group, a $27 billion international healthcare and chemicals group based in Leverkusen, Germany. The Bayer Group stock is a component of the DAX and is listed on the New York Stock Exchange (ticker symbol: BAY).

About GSK
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are discussed under risk factors in the Company's Preliminary Announcement of Results for the Year Ended 31st December 2002.